• Terms and Conditions
  • Privacy Policy
  • DMCA
  • Disclaimer
  • Cookie Privacy Policy
  • Contact Us
Sixsense News
Advertisement
  • Home
  • Business
  • Economy
  • Fintech
  • Finance
  • Insurance
  • Market
  • Startups
No Result
View All Result
  • Home
  • Business
  • Economy
  • Fintech
  • Finance
  • Insurance
  • Market
  • Startups
No Result
View All Result
Sixsense News
No Result
View All Result
Home Market

Roche’s test wins FDA nod to identify certain breast cancer patients eligible for Enhertu

Sixsense News by Sixsense News
October 4, 2022
in Market
0


trabantos/iStock via Getty Images

The U.S. Food and Drug Administration (FDA) approved Roche’s (OTCQX:RHHBY) (OTCQX:RHHBF) PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test to identify patients with metastatic breast cancer with low HER2 expression for whom Enhertu can be used as a targeted treatment.

The test is the only FDA approved companion diagnostic indicated to assess HER2 low status in patients with metastatic breast cancer, the company said in an Oct. 4 press release.

The Swiss pharma giant added that the FDA approval of the new HER2 low indication expands on the intended use of its on-market PATHWAY anti-HER2 (4B5) test.

The test was used as part of a study called DESTINY-Breast04 by AstraZeneca (AZN) and Daiichi Sankyo (OTCPK:DSKYF) (OTCPK:DSNKY), the developers of Enhertu (fam-trastuzumab deruxtecan-nxki), to identify patients whose tumors expressed low levels of HER2 protein, Roche added.

A companion diagnostic is a test that helps determine if a particular therapy’s benefit to patients will outweigh any potential serious side effects or risks, and also helps identify patients who are more likely to benefit from a particular drug, according to the FDA.

In August, the FDA approved Guardant Health’s (GH) liquid biopsy test Guardant360 CDx as a companion diagnostic to to identify patients with a type lung cancer who could be treated with Enhertu.



Source link

Related articles

The Fed Starts Playing “Mind Games” as Rates Rise, Home Prices Fall

March 31, 2023

China manufacturing growth eases in March to 51.9

March 31, 2023
Tags: breastcancereligibleEnhertuFDAidentifynodpatientsRochesTestwins

Related Posts

The Fed Starts Playing “Mind Games” as Rates Rise, Home Prices Fall

by On The Market Podcast Presented by Fundrise
March 31, 2023
0

Last week, the Federal Reserve both surprisingly and unsurprisingly raised rates. For weeks leading up to this meeting, investors had...

China manufacturing growth eases in March to 51.9

by Sixsense News
March 31, 2023
0

The official NBS Manufacturing PMI declined to 51.9 in March of 2023 from February's near 11-year high of 52.6 but...

Asia FX muted, dollar sinks ahead of PCE inflation data By Investing.com

by Investing.com
March 31, 2023
0

© Reuters By Ambar Warrick Investing.com -- Most Asian currencies moved little on Friday as the dollar weakened on signs...

why is sensex rising: Sensex zooms 750 points on last day of FY23: Top 5 factors behind the rally

by Sixsense News
March 31, 2023
0

NEW DELHI: Led by buying across sectors, Sensex rallied up to 749 points while Nifty went near the 17,300 mark...

China needs to step up fiscal policy help for its economy

by Reuters
March 31, 2023
0

© Reuters. FILE PHOTO: The sign of China's Ministry of Finance is pictured in Beijing, China August 23, 2018. REUTERS/Jason...

Load More

Asian shares ride high in Q1 but keep vigil on inflation By Reuters

March 31, 2023

The Fed Starts Playing “Mind Games” as Rates Rise, Home Prices Fall

March 31, 2023

Japan to restrict chipmaking equipment exports as it aligns with US China curbs By Reuters

March 31, 2023

China manufacturing growth eases in March to 51.9

March 31, 2023

Asia FX muted, dollar sinks ahead of PCE inflation data By Investing.com

March 31, 2023

IMF urges BOJ to allow longer yields to move more flexibly By Reuters

March 31, 2023
Sixsense News

© 2022 Sixsense News All Rights Reserved.

Navigate Site

  • Terms and Conditions
  • Privacy Policy
  • DMCA
  • Disclaimer
  • Cookie Privacy Policy
  • Contact Us

Follow Us

No Result
View All Result
  • #3158 (no title)
  • Business
  • Economy
  • Finance
  • Fintech
  • Insurance
  • Market
  • Startups

© 2022 Sixsense News All Rights Reserved.